Legis Daily

Uterine Fibroid Research and Education Act of 2020

USA116th CongressS-4397| Senate 
| Updated: 8/3/2020
Kamala D. Harris

Kamala D. Harris

Democratic Senator

California

Cosponsors (3)
Chris Van Hollen (Democratic)Cory A. Booker (Democratic)Richard Blumenthal (Democratic)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Uterine Fibroid Research and Education Act of 2020 This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues). Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies. In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services. Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 24, 2020

Latest Companion Bill Action

HR 116-6383
Introduced in House
Aug 3, 2020
Introduced in Senate
Aug 3, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • March 24, 2020

    Latest Companion Bill Action

    HR 116-6383
    Introduced in House


  • August 3, 2020
    Introduced in Senate


  • August 3, 2020
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • HR 116-6383: Uterine Fibroid Research and Education Act of 2020
Congressional oversightHealth care coverage and accessHealth personnelHealth promotion and preventive careHealth technology, devices, suppliesMedicaidMedical researchMinority healthPrescription drugsResearch administration and fundingSex and reproductive healthWomen's health

Uterine Fibroid Research and Education Act of 2020

USA116th CongressS-4397| Senate 
| Updated: 8/3/2020
Uterine Fibroid Research and Education Act of 2020 This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues). Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies. In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services. Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 24, 2020

Latest Companion Bill Action

HR 116-6383
Introduced in House
Aug 3, 2020
Introduced in Senate
Aug 3, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • March 24, 2020

    Latest Companion Bill Action

    HR 116-6383
    Introduced in House


  • August 3, 2020
    Introduced in Senate


  • August 3, 2020
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Kamala D. Harris

Kamala D. Harris

Democratic Senator

California

Cosponsors (3)
Chris Van Hollen (Democratic)Cory A. Booker (Democratic)Richard Blumenthal (Democratic)

Health, Education, Labor, and Pensions Committee

Health

Related Bills

  • HR 116-6383: Uterine Fibroid Research and Education Act of 2020
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightHealth care coverage and accessHealth personnelHealth promotion and preventive careHealth technology, devices, suppliesMedicaidMedical researchMinority healthPrescription drugsResearch administration and fundingSex and reproductive healthWomen's health